Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
December 9, 2020

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

By Matsuoka
Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle

Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Cancer Antigen 15-3 (CA 15-3) Breast Tumor Standard Grade

GWB-F0C8B0 25000 Unit Ask for price

Cancer Antigen 125 (CA 125) Standard Grade

GWB-565817 25000 Unit Ask for price

Cancer Antigen 125 (CA 125) Standard Grade

GWB-A9985A 50000 Unit Ask for price

Cancer Antigen 72-4 (CA 72-4) Standard Grade

GWB-626B6B 10 KU Ask for price

Cancer Antigen 72-4 (CA 72-4) Standard Grade

GWB-254330 50000 Unit Ask for price

Cancer Antigen 19-9 (CA 19-9) Standard Grade

GWB-1CA918 50000 Unit Ask for price

Cancer Antigen 19-9 (CA 19-9) Standard Grade

GWB-EECE0C 50000 Unit Ask for price

CA15-3 Cancer Antigen (CA15-3, Breast Tumor Protein)

MBS651681-10KUnits 10KUnits
EUR 1050

CA15-3 Cancer Antigen (CA15-3, Breast Tumor Protein)

MBS651681-5x10KUnits 5x10KUnits
EUR 4565

CA15-3 Cancer Antigen (Breast Cancer)

MBS651656-50KUnits 50KUnits
EUR 1890

CA15-3 Cancer Antigen (Breast Cancer)

MBS651656-5x50KUnits 5x50KUnits
EUR 8345

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody Pair Kit (with Standard)

MBS2103664-10x96Tests 10x96Tests
EUR 1480

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody Pair Kit (with Standard)

MBS2103664-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1600

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody Pair Kit (with Standard)

MBS2103664-5x96Tests 5x96Tests
EUR 935

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody Pair Kit (with Standard)

MBS2103664-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 1010

Cancer Antigen 15-3 (CA 15-3) Low Cross Grade

GWB-E47BC0 10000 Unit Ask for price

Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody Pair Kit (with Standard)

MBS2103665-10x96Tests 10x96Tests
EUR 1480

Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody Pair Kit (with Standard)

MBS2103665-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1600

Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody Pair Kit (with Standard)

MBS2103665-5x96Tests 5x96Tests
EUR 935

Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody Pair Kit (with Standard)

MBS2103665-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 1010

Human Breast Tumor Cancer Cells

ABC-HP013X 1 vial Ask for price
Description: Human breast cancer cells are isolated from human invasive ductal breast carcinoma sample. Human breast cancer cells are positive for pan-Cytokeratin, MGB-1 and MUC-1. CD90 staining shows that cultures are free of fibroblasts in 99%.

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100267-10x96Tests 10x96Tests
EUR 1595

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100267-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1715

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100267-5x96Tests 5x96Tests
EUR 1005

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100267-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 1080

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100292-10x96Tests 10x96Tests
EUR 1595

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100292-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1715

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100292-5x96Tests 5x96Tests
EUR 1005

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100292-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 1080

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100265-10x96Tests 10x96Tests
EUR 1410

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100265-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1530

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100265-5x96Tests 5x96Tests
EUR 895

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100265-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 970

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100266-10x96Tests 10x96Tests
EUR 1445

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100266-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1570

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100266-5x96Tests 5x96Tests
EUR 915

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody Pair Kit (with Standard)

MBS2100266-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 990

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100290-10x96Tests 10x96Tests
EUR 1410

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100290-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1530

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100290-5x96Tests 5x96Tests
EUR 895

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100290-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 970

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100291-10x96Tests 10x96Tests
EUR 1515

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100291-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1640

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100291-5x96Tests 5x96Tests
EUR 960

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody Pair Kit (with Standard)

MBS2100291-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 1035

Cancer Antigen 15-3 (CA 15-3) Cell Culture Low Cross Grade

GWB-553B7B 10000 Unit Ask for price

Breast tumor antigen (CA-15-3) Antibody, Concentrate

MAB521C 0.2ml
EUR 455

Breast Tumor Antigen

30C-CP1096B 50 KU
EUR 733
Description: Partially Purified Native Breast Tumor Antigen

Human Cancer PrimaCell4: Breast Tumor Cells

2-96027 1 Kit Ask for price

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2)

MBS6507054-02mg 0.2mg
EUR 700

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2)

MBS6507054-5x02mg 5x0.2mg
EUR 3010

Human Cancer Antigen CA15-3 Antigen Grade

GWB-C54ECC 50000 Unit Ask for price

Human Cancer Antigen CA15-3 Antigen Grade

MBS318065-50KUnits 50KUnits
EUR 2585

Human Cancer Antigen CA15-3 Antigen Grade

MBS318065-5x50KUnits 5x50KUnits
EUR 11460

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (AP)

MBS6241881-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (AP)

MBS6241881-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (HRP)

MBS6244012-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (HRP)

MBS6244012-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (PE)

MBS6244545-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (PE)

MBS6244545-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (APC)

MBS6242414-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (APC)

MBS6242414-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (FITC)

MBS6243479-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (FITC)

MBS6243479-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (Biotin)

MBS6242946-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (Biotin)

MBS6242946-5x01mL 5x0.1mL
EUR 4310

Breast Cancer Antigen CA15-3 Enzyme Immunoassay Test Kit

GWB-150A4D ELISA_Kits Ask for price

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 405)

MBS6245078-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 405)

MBS6245078-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 490)

MBS6245611-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 490)

MBS6245611-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 750)

MBS6247210-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 750)

MBS6247210-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 550)

MBS6246144-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 550)

MBS6246144-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 650)

MBS6246677-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 650)

MBS6246677-5x01mL 5x0.1mL
EUR 4310

Breast cancer and normal tissue array with stage and grade info

BR8012 each
EUR 306
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014

Breast tumor antigen (CA-15-3) Antibody, Ready-To-Use

MAB521P 5ml
EUR 445

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium

9-46027 5 x 100 ml Ask for price

Breast fibroadenoma, breast tissue and breast cancer array, including pathology grade, TNM and clinical stage, 71 cases/80 cores

BR8010 row: 8; column: 10; cores: 80; cases: 71
EUR 306
Description: Breast fibroadenoma, breast tissue and breast carcinoma microarray, containing 7 cases of normal breast, 3 adjacent normal breast tissue, 20 fibroadenoma, 10 invasive lobular carcinoma, 30 invasive ductal carcinoma and 10 matched or matched lymph node metastatic carcinoma, single core per block

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody

20-abx148333
  • Ask for price
  • Ask for price
  • 100 ug
  • 50 ug

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells

9-80027 1 x 100 ml Ask for price

Human tumor marker CA549 for breast cancer ELISA Kit

SL3271Hu 96 Tests
EUR 468

Human Cancer/Testis Antigen 1B (CTAG1B) Antibody Pair Kit (with Standard)

MBS2104021-10x96Tests 10x96Tests
EUR 1480

Human Cancer/Testis Antigen 1B (CTAG1B) Antibody Pair Kit (with Standard)

MBS2104021-10x96TestsMBS2090685AbPairsSupportPack110x96Tests 10x96Tests+MBS2090685(AbPairsSupportPack1,10x96Tests)
EUR 1600

Human Cancer/Testis Antigen 1B (CTAG1B) Antibody Pair Kit (with Standard)

MBS2104021-5x96Tests 5x96Tests
EUR 935

Human Cancer/Testis Antigen 1B (CTAG1B) Antibody Pair Kit (with Standard)

MBS2104021-5x96TestsMBS2090685AbPairsSupportPack15x96Tests 5x96Tests+MBS2090685(AbPairsSupportPack1,5x96Tests)
EUR 1010

Cancer Antigen 19-9 (Gastrointestinal Cancer) Calibrator Grade

MBS319684-50KUnits 50KUnits
EUR 440

Cancer Antigen 19-9 (Gastrointestinal Cancer) Calibrator Grade

MBS319684-5x50KUnits 5x50KUnits
EUR 1800

Cancer Antigen 19-9 (Gastrointestinal Cancer) Calibrator Grade

MBS319694-50KUnits 50KUnits
EUR 515

Cancer Antigen 19-9 (Gastrointestinal Cancer) Calibrator Grade

MBS319694-5x50KUnits 5x50KUnits
EUR 2155

Gastrointestinal Cancer Antigen (CA 19-9), antigen grade

CA1991-N-10 10 KU
EUR 634.8

Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores

FMG252 row: 4; column: 6; cores: 24; cases: 12
EUR 78
Description: Breast carcinoma with matched breast tissue microarray, containing 12 cases breast carcinoma with matched cancer adjacent breast tissue, duplicate cores per case

Breast cancer tissue array (pathology grade:1,2,3), including pathology grade, TNM and clinical stage, 45 cases/90 cores

BR901 row: 9; column: 10; cores: 90; cases: 45
EUR 270
Description: Breast invasive carcinoma of no special type tissue microarray, containing 40 cases of invasive carcinoma of no special type, 5 adjacent normal breast tissue, duplicate core per case

Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge, 31 cases/50 cores

BRE502 row: 6; column: 9; cores: 50; cases: 31
EUR 162
Description: Breast carcinoma with breast tissue microarray, containing 16 cases of invasive carcinoma of no special type, 1 invasive lobular carcinoma, 3 medullary carcinoma, 4 invasive carcinoma, 1 metaplastic carcinoma, plus 25 adjacent normal or cancer adjacent breast tissue (19 matched with cancer), single core per block

Cancer Antigen 125 (CA 125) Low Cross Grade

GWB-87F2DB 10000 Unit Ask for price

OPMA04167-50KIU - Human Cancer Antigen CA15-3 Antigen Grade Protein

OPMA04167-50KIU 50KU
EUR 2999

Cancer Antigen CA50, Calibrator Grade Protein

GWB-T00050 50KU Ask for price

Breast cancer tissue array, with adjacent normal tissue and cancer adjacent breast tissue, including pathology grade,TNM and clinical stage, 45 cases/63 cores

FMG631 row: 7; column: 9; cores: 63; cases: 45
EUR 270
Description: Breast invasive carcinoma of no special type tissue microarray, containing 21 cases of invasive carcinoma of no special type, with adjacent normal and cancer adjacent breast tissue (18 matched with cancer), single core per block

(untagged)-Human breast cancer antigen NY-BR-1.1 mRNA, partial cds

SC315066 10 µg Ask for price

Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores, replacing BR1504b

BR1504c row: 10; column: 15; cores: 150; cases: 75
EUR 306
Description: Breast carcinoma with breast tissue microarray, containing 70 cases of invasive ductal carcinoma, 4 adjacent normal breast tissue and 1 breast tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position)

Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 188 cases/208 cores, replacing BR2085b

BR2085c row: 13; column: 16; cores: 208; cases: 188
EUR 546
Description: Breast carcinoma with breast tissue microarray, containing 144 cases of invasive carcinoma of no special type, 24 invasive lobular carcinoma, 1 breast tissue, 19 adjacent normal breast tissue, single core per case of carcinoma, duplicate cores per case of breast tissue and adjacent normal breast tissue

Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c

FBR087d row: 3; column: 8; cores: 24; cases: 6
EUR 66
Description: Breast carcinoma with breast tissue microarray, containing 3 cases of invasive carcinoma of no special type, 1 invasive lobular carcinoma, 2 breast tissue, quadruple cores per case, 2 serial sections, divided into two identical 12 core arrays for testing different antibody dilutions

Breast Cancer and 8 types of tumor (middle advanced stage)tissue array

BR20838a each
EUR 474
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838

Cancer Antigen CA242 (Gastrointestinal Cancer) Calibrator Grade Protein

GWB-T00229 50KU Ask for price

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401307-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401307-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401308-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401308-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401309-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401309-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401310-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401310-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401311-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401311-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401312-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401312-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401313-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401313-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401314-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401314-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401315-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401315-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401316-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401316-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401317-01mL 0.1mL
EUR 1040

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6401317-5x01mL 5x0.1mL
EUR 4540

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260380-01mL 0.1mL
EUR 970

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260380-5x01mL 5x0.1mL
EUR 4220

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260381-01mL 0.1mL
EUR 970

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260381-5x01mL 5x0.1mL
EUR 4220

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260382-01mL 0.1mL
EUR 1185

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260382-5x01mL 5x0.1mL
EUR 5180

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260383-01mL 0.1mL
EUR 1185

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6260383-5x01mL 5x0.1mL
EUR 5180

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6263953-01mL 0.1mL
EUR 970

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6263953-5x01mL 5x0.1mL
EUR 4220

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6263954-01mL 0.1mL
EUR 970

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6263954-5x01mL 5x0.1mL
EUR 4220

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6263955-01mL 0.1mL
EUR 1185

MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass

MBS6263955-5x01mL 5x0.1mL
EUR 5180
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.